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1  | INTRODUC TION
Coronavirus disease 2019 (COVID-19) is caused by severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2) (Yuki, Fujiogi, & 
Koutsogiannaki, 2020). Since the introduction of COVID-19 to the 
human population in the Chinese city of Wuhan, it has spread rapidly 
across the globe and was officially considered a pandemic in March 
2020 (World Health Organization, 2020; Yuki et al., 2020). As of 16 
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Abstract
Objective: Olfactory and taste dysfunction (OTD) is a potential neurological manifes-
tation of coronavirus-2019 (COVID-19). We aimed to investigate the diagnostic value 
of symptoms of anosmia and dysgeusia for COVID-19.
Methods: A comprehensive electronic search was conducted using PubMed, 
MEDLINE, Scopus, Cochrane database, and Google Scholar from 1 June 2020 to 12 
June 2020. All studies reporting symptoms of anosmia and dysgeusia in COVID-19-
positive patients were included. A total of 23 studies were included in the systematic 
review.
Results: Symptoms of anosmia and dysgeusia were frequently reported by COVID-
19-positive patients. Symptoms were more common in females and in younger pa-
tients. There was no direct association between the severity of COVID-19 and the 
presence of symptoms. However, some evidence was found for a longer duration of 
these symptoms and increased severity of COVID-19 infection in young patients.
Conclusion: OTD is commonly reported by COVID-19 patients. Due to limited litera-
ture on the association between OTD and COVID-19, it is currently not possible to 
conclude that these symptoms alone can be used to diagnose COVID-19. However, 
the presence of OTD can potentially be used as a screening tool for COVID-19 espe-
cially in young and female patients. Further research is required to establish the true 
diagnostic value of these symptoms and efficacy as screening tools for COVID-19 
patients.
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August 2020, there have been > 21 million cases with > 700,000 
deaths globally (World Health Organisation, 2019). Coronaviruses 
(CoV) belongs to the Coronavirinae subfamily and are known for 
their microscopic crown-like appearance (Chen, Liu, & Guo, 2020a; 
Ren et al., 2020). The COVID-19 pathogen is a human RNA virus and 
belongs to the β-CoVs in the CoV phylogenetic tree (Chen, Liu, et al., 
2020). Genome examinations reveal that the novel SARS-CoV-2 is 
87.99% genetically similar to bats SARS-like coronavirus and genet-
ically distant from the previously known SARS and MERS viruses 
(Lovato & Filippis, 2020; Ren et al., 2020). The virus is transmittable 
from person-to-person via respiratory droplets and has a basic re-
productive number of approximately 1–3 (Flahault, 2020; Lovato & 
Filippis, 2020).
Studies report that COVID-19 patients can present with fever, 
dry cough, dyspnea, and fatigue (Guan et al., 2020; Lovato & 
Filippis, 2020). In severe cases, the infection can cause viral pneu-
monia leading to severe acute respiratory distress syndrome or 
even death (Guan et al., 2020; Lovato & Filippis, 2020). Symptoms 
of pharyngodynia, nasal congestion, and rhinorrhoea have also been 
reported in infected patients (Lovato & Filippis, 2020). Sense of smell 
is controlled by the olfactory cranial nerve (Cranial & Nerve). The 
European Rhinology society reported that a significant number of 
COVID-19 patients (20%–60%) appear to have loss of smell also 
known as anosmia (IMPORTANT INFO ON, 2020). Furthermore, 
reports from China, South Korea, and Italy also reported anosmia 
in COVID-19 patients (Entuk.org., 2020; Guan et al., 2020; Kang, 
Cho, Lee, Kim, & Park, 2020; Lee, Min, Lee, & Kim, 2020). In the UK, 
anosmia is classed as an official symptom for COVID-19 (Statement 
from the UK, 2020). Anosmia may be the first presenting symptom, 
preceding the occurrence of other COVID-19 symptoms such as 
cough and fever (Kang et al., 2020). Interestingly, changes in sense 
of taste also known as dysgeusia have also been reported in infected 
patients (Carrillo-Larco & Altez-Fernandez, 2020).
The presence of anosmia and dysgeusia may help neurologists 
and otolaryngologists identify patients with COVID-19 early, al-
lowing prompt management and infection control procedures to be 
implemented. The current study aimed to systematically review the 
current literature on the clinical presentation of COVID-19, specifi-
cally focussing on the symptoms of anosmia and dysgeusia and their 
diagnostic value in COVID-19 patients.
2  | METHODS
2.1 | Electronic database search
A comprehensive literature search was conducted using PubMed, 
Medline, Scopus, Cochrane database, and Google Scholar using 
MeSH words including: “COVID-19," “Coronavirus 2019,” “Anosmia,” 
“Dysgeusia.” The systematic review was carried out according to 
the Preferred Reporting Items for Systematic Reviews and Meta-
analysis (PRISMA) (Moher, Liberati, Tetzlaff, & Altman, 2009). We 
examined articles and abstracts available in the English language. 
Literature was screened for original data, and any related references 
were retrieved and checked manually for other relevant studies.
2.2 | Inclusion and exclusion criteria
Studies were included if the following criteria were met: (a) Articles 
were original reports, (b) studies included laboratory-confirmed 
COVID-19 patients, (c) studies reported details of clinical presen-
tation, and (d) the reports were published in the English language. 
Exclusion criteria included: (a) study design: case report, editorial, 
letter to the editor, or review; (b) studies reporting symptoms in 
children/infants.
2.3 | Data extraction
All studies were screened by two authors independently (KP and SI). 
Any disagreements were resolved by discussion between the review 
team members. The extracted data were then cross-checked by an-
other author (SAZ) to validate its accuracy. Included studies were 
analyzed to extract all available data and assure eligibility for all pa-
tients. Description data of patients including age, sex, clinical symp-
toms, underlying medical conditions, and outcomes were extracted 
and recorded for all studies.
2.4 | Methodological assessment of the studies
Quality Assessment of the included qualitative studies was con-
ducted using the Newcastle-Ottawa Scale (Table 1) (Wells et al., 
2020). The scale was devised specifically to allow quality assessment 
of the nonrandomized studies included in the systematic review. The 
scale allows assessment of bias using a star-based rating system with 
a maximum score of 9 indicating a low risk of bias and a minimum of 
0	 indicating	the	highest	risk	 (Wells	et	al.,	2020).	Scores	≥	7	gener-
ally represent a low risk of bias (Wells et al., 2020). The quality of 
included studies was rated by two of the authors (SAZ and SI).
2.5 | Statistical analysis
It was not possible to do pooled analysis due to high heterogeneity 
in study design and assessment.
3  | RESULTS
3.1 | Retrieving studies
A search was started on 10 June 2020, and the last search was on 
20 June 2020. A total of 150 articles were retrieved from differ-
ent databases. After removing duplicates and screening titles and 
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abstracts of studies, we identified 35 studies potentially relevant to 
the topic. The full text screening of the articles allowed exclusion 
of 12 studies that did not meet our inclusion criteria. The remaining 
23 studies were considered to be eligible for our systematic review. 
Figure 1 shows a summary of the selection process and criteria.
3.2 | Assessment of the studies
All 23 studies included were relevant for the review topic. (Beltrán-
Corbellini et al., 2020; Bénézit et al., 2020; Boscolo-Rizzo et al., 2020; 
Carignan et al., 2020; Giacomelli et al., 2020; Hopkins, Surda, & 
Kumar, 2020; Hopkins, Surda, Whitehead, & Kumar, 2020; Iravani 
et al., 2020; Kaye, Chang, Kazahaya, Brereton, & Denneny, 2020; 
Klopfenstein et al., 2020; Kosugi et al., 2020; Lechien, Cabaraux, 
& Chiesa-Estomba et al., 2020a, 2020b; Lechien et al., 2020; Lee 
et al., 2020; Levinson et al., 2020; Mao et al., 2020; Moein et al., 2020; 
Spinato et al., 2020; Vaira et al., 2020; Vaira, Salzano, Deiana, & De 
Riu, 2020; Wee et al., 2020; Yan, Faraji, Prajapati, Ostrander, & 
DeConde, 2020) There were no randomized control trials, and stud-
ies were mainly retrospective (20) or prospective (3) case-series, 
case–control, cohort, cross-sectional studies (Beltrán-Corbellini 
et al., 2020; Bénézit et al., 2020; Boscolo-Rizzo et al., 2020; Carignan 
et al., 2020; Giacomelli et al., 2020; Hopkins, Surda, & Kumar, 
2020; Hopkins, Surda, Whitehead, et al., 2020; Iravani et al., 2020; 
Kaye et al., 2020; Klopfenstein et al., 2020; Kosugi et al., 2020; 
Lechien, Cabaraux, & Chiesa-Estomba et al., 2020a, 2020b; Lechien 
et al., 2020; Lee et al., 2020; Levinson et al., 2020; Mao et al., 2020; 
Moein et al., 2020; Spinato et al., 2020; Vaira, Hopkins, Salzano 
et al., 2020; Vaira, Salzano, Deiana, & De Riu, 2020; Wee et al., 2020; 
Yan et al., 2020). Quality of the studies included in the review was 
assessed using the Newcastle-Ottawa Scale (Table 1) (Wells et al., 
2020). A “good” quality score required 3 or 4 stars in selection, 1 or 
2 stars in comparability, and 2 or 3 stars in outcomes (Wells et al., 
2020). A “fair” quality score required 2 stars in selection, 1 or 2 stars 
in comparability, and 2 or 3 stars in outcomes (Wells et al., 2020). A 
“poor” quality score reflected 0 or 1 star(s) in selection, or 0 stars 
in comparability, or 0 or 1 star(s) in outcomes (Wells et al., 2020). 
Most studies were poor quality, with only 6 studies identified to be 
of good quality. There is high risk of reporting bias as most studies 
utilized self-report questionnaires. These questionnaires are subjec-
tive, and it may be possible that some patients exaggerated or over 
reported their symptoms. Confounders such as the presence of pre-
existing respiratory or otolaryngology disease were not universally 
accounted for.
3.3 | Patient background
We included results from 12,314 patients in this review (Table 2) 
(Beltrán-Corbellini et al., 2020; Bénézit et al., 2020; Boscolo-
Rizzo et al., 2020; Carignan et al., 2020; Giacomelli et al., 2020; 
Hopkins, Surda, & Kumar, 2020; Hopkins, Surda, Whitehead, et al., 
2020; Iravani et al., 2020; Kaye et al., 2020; Klopfenstein et al., 
2020; Kosugi et al., 2020; Lechien, Cabaraux, & Chiesa-Estomba 
et al., 2020a, 2020b; Lechien et al., 2020; Lee et al., 2020; Levinson 
F I G U R E  1   PRISMA flow chart showing 
the selection process for included studies
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et al., 2020; Mao et al., 2020; Moein et al., 2020; Spinato et al., 2020; 
Vaira et al., 2020, 2020; Wee et al., 2020; Yan et al., 2020). Patient 
demographics were not reported by all studies but in those that 
had, most patients were male with the age of the patients rang-
ing from 32 to 60 years (Beltrán-Corbellini et al., 2020; Carignan 
et al., 2020; Giacomelli et al., 2020; Hopkins, Surda, Whitehead, 
et al., 2020; Kaye et al., 2020; Klopfenstein et al., 2020; Kosugi 
et al., 2020; Lechien, Cabaraux, & Chiesa-Estomba et al., 2020a, 
2020b; Lechien et al., 2020; Levinson et al., 2020; Mao et al., 2020; 
Moein et al., 2020; Spinato et al., 2020; Vaira et al., 2020, 2020; 
Yan et al., 2020) The presence of comorbidities especially cardio-
vascular disease, cerebrovascular disease, and diabetes mellitus has 
been associated with increased risk of COVID-19 infection and 
increased severity of the infection. Comorbidities were also not 
reported by most studies, but in those that had, hypertension (4.7%–
28.3%) was the most common disease found in COVID-19 patients. 
(Klopfenstein et al., 2020; Kosugi et al., 2020; Lechien, Cabaraux, & 
Chiesa-Estomba et al., 2020a, 2020b; Lechien et al., 2020; Levinson 
et al., 2020; Mao et al., 2020; Moein et al., 2020; Spinato et al., 2020; 
Yan et al., 2020).
3.4 | Prevalence of anosmia and dysgeusia
The prevalence of olfactory and taste dysfunction (OTD) in COVID-
19 varies widely in the literature (Table 2). A large multicentre study 
from Europe reports over 85% of patients who have been confirmed 
positive for COVID-19 report OTD (Lechien et al., 2020). This pro-
portion remains consistently high in the absence of nasal obstruction 
(Hopkins, Surda, & Kumar, 2020). Beltrán-Corbellini et al. conducted 
a case–control study comparing the prevalence of olfactory and gus-
tatory dysfunction in patients with COVID-19 compared to those 
with other influenza-like diseases (Beltrán-Corbellini et al., 2020). 
The results corroborated that of Leichen et al., with over 80% re-
porting smell disorders and over 90% reporting taste dysfunction 
(Lechien, Cabaraux, & Chiesa-Estomba et al., 2020a). Both symp-
toms were significantly more likely to occur whether the patient was 
COVID-19-positive. In contrast, a smaller study done by Giamecello 
et al. sets a smaller prevalence, with 34% of their sample report-
ing at least one form of taste and smell dysfunction (Giacomelli 
et al., 2020).
OTD exists on a spectrum, from hyposmia and hypogeusia to 
anosmia and ageusia. True absence of taste or smell is rarer than 
dysfunction. Vaira et al. reported the results of a case series of 72 
COVID-19 patients who underwent objective olfactory and gusta-
tory testing. An assessment revealed 83.3% and 47.1% had hypos-
mia and hypogeusia, respectively. This contrasts with anosmia (2.8%) 
and ageusia (1.4%) (Vaira et al., 2020). Klopfenstein et al. conducted 
a retrospective cohort study that set the prevalence of anosmia at 
47% and dysgeusia at 85% in its sample (Klopfenstein et al., 2020). 
It is important to regard nasal obstruction as a possible explana-
tion for OTD. Lechien et al. and Spinato et al. report a minority of 
patients with concomitant nasal obstruction, but this aspect is not 
widely accounted for in the literature (Lechien, Cabaraux, & Chiesa-
Estomba et al., 2020b; Spinato et al., 2020). A consistent feature 
in the evidence base is that OTD is significantly more common in 
younger patients and those who are female. (Klopfenstein et al., 
2020; Lechien, Cabaraux, & Chiesa-Estomba et al., 2020b; Spinato 
et al., 2020; Vaira et al., 2020)
3.5 | Other symptoms
In most studies that reported olfactory or gustatory dysfunc-
tion, a range of other symptoms such as fever, cough, headache, 
fatigue, and arthralgia/myalgia were also reported (Table 3) 
(Carignan et al., 2020; Giacomelli et al., 2020; Klopfenstein et al., 
2020; Kosugi et al., 2020; Lechien, Cabaraux, & Chiesa-Estomba 
et al., 2020a, 2020b; Lechien et al., 2020; Mao et al., 2020; 
Moein et al., 2020; Spinato et al., 2020; Vaira et al., 2020; Wee 
et al., 2020; Yan et al., 2020). The most commonly reported symp-
tom in the majority of the studies was fever with a few reporting 
cough to be the most common. In contrast, Yan et al. reported 
fatigue as the most common symptom with 81.4% of patients with 
the symptom (Yan et al., 2020) This is consistent with Klopenstein 
et al. which reported 93% of COVID-19 patients had fatigue 
(Klopfenstein et al., 2020; Yan et al., 2020). Interestingly, studies 
have also reported anorexia as a symptom. (Carignan et al., 2020; 
Kosugi et al., 2020; Mao et al., 2020; Moein et al., 2020; Spinato 
et al., 2020) The presence of anorexia varies between 3% and 
56% (Carignan et al., 2020; Kosugi et al., 2020; Mao et al., 2020; 
Moein et al., 2020; Spinato et al., 2020). It is important to note 
that dysfunction in a sense of taste or smell could cause changes 
in appetite. Therefore, an examination of olfactory and gustatory 
function may be warranted in patients with anorexia.
3.6 | Severity
There is significant variability in the reported severity of symptoms 
(Table 2). In a cohort of 72 patients, administering the Connecticut 
Chemosensory Clinical Research Centre Orthonasal Olfaction test 
(CCCRC) revealed mild to moderate hyposmia as the most common 
presentation of OTD, while complete anosmia was only present in 
2.8% of the cohort. (Vaira et al., 2020) There is similar variability in 
the presentation of taste dysfunction. In the same cohort, mild to 
moderate hypogeusia were common while there was only one pa-
tient with complete ageusia (complete loss of taste sensation). (Vaira 
et al., 2020) In another assessment of OTD, a cohort of 283 patients 
in Italy were assessed using a telephone interview after positive na-
sopharyngeal and throat swabs. Here, the Sino-nasal Outcome Test 
22 (SNOT-22) was utilized, and the median score of the 130 patients 
reporting symptoms was four (Spinato et al., 2020). The SNOT-22 
uses a scale of zero to five, with five indicating the symptoms are 
“as bad as it can be” and the score of four would indicate the OTD is 
severe (Hopkins, Gillett, Slack, Lund, & Browne, 2009). Importantly, 
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this study presents an objective assessment of OTD where other 
studies rely on self-reported questionnaires.
While there is a variance in the severity of OTD in COVID-19 
patients, there has been research into the presence of OTD as a 
predictor of severe infection. It should be noted that there is still 
uncertainty in defining a severe infection; however, numerous prox-
ies have been used in literature. Interestingly, multivariable logistic 
regression of 169 patients in San Diego showed that the presence of 
normosmia was independently associated with hospitalization with 
hyposmia or anosmia 10-fold less likely to be admitted, suggesting 
alterations in olfaction are associated with milder infections (Yan 
et al., 2020). However, further work has failed to recreate the same 
result. Vaira et al. show that there exists no correlation between 
the severity of disease and the CCCRC score using pneumonia as a 
marker of severity (Vaira et al., 2020). This is further highlighted in 
work by Mao et al., while the most common peripheral nervous sys-
tem symptoms were OTD, the presence of either smell or taste im-
pairment had no bearing on the severity of disease (Mao et al., 2020).
3.7 | Recovery
As seen with severity, there is marked variability in the recovery 
from the OTD (Table 2). In a retrospective analysis of 253 patients 
with COVID-19 in Brazil, an online survey indicated that full recov-
ery had a median duration of 12.5 days and with a median follow-up 
of 31 days – 121 patients had fully recovered in that time (Kosugi 
et al., 2020). Similarly, another retrospective analysis of 42 pa-
tients in Israel showed a median recovery of 7.6 days in 35.7% of 
the cohort reporting anosmia (Levinson et al., 2020). However, the 
follow-up period was cut short and as such poses a question regard-
ing the true value of recovery. In further studies, the median dura-
tion does appear within the range of 1–2 weeks (Lee et al., 2020). 
Total recovery time among the entire cohort was not well reported 
among the studies identified; however, Lee et al. noted it took over 
3 weeks for a cohort of 3,191 patients in South Korea to fully re-
cover (Lee et al., 2020). The younger population (ages 20–39) were 
prone to have a longer duration of anosmia than older cohorts (Lee 
et al., 2020).
3.8 | Discussion
A large COVID-19 case series published by the Chinese Centre of 
Disease Control and prevention reported that among a total of 72, 
314 COVID-19 cases, a total of 22% of patients were identified as 
suspected cases and 15% were clinically diagnosed based on clinical 
symptoms (Wu & McGoogan, 2020). The most common symptoms 
were reported to be fever and cough, with no detailed description 
of any other symptoms (Wu & McGoogan, 2020). Increasing evi-
dence shows that symptoms of anosmia and dysgeusia are related 
to COVID-19 (Lovato & Filippis, 2020; Zayet et al., 2020). In March 
2020, American Academy of Otolaryngology-Head and Neck Surgery T
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suggested that the symptoms of anosmia and dysgeusia should be 
included in the list of screening tools for COVID-19 as these symp-
toms are frequently reported by patients that ultimately test positive 
for COVID-19 (AAO-HNS: Anosmia, Hyposmia). Symptoms of OTD 
should prompt self-isolation and testing for COVID-19. Suspected 
COVID-19 cases should be isolated and health personnel in contact 
should wear appropriate personal protective equipment such as wa-
terproof gowns, gloves, goggles, and surgical masks or FFP2 masks 
(AAO-HNS: Anosmia, Hyposmia; Lovato & Filippis, 2020). This sys-
tematic review aimed to investigate the diagnostic value of anosmia 
and dysgeusia for COVID-19.
Anosmia and dysgeusia were frequently reported in patients 
who tested positive for COVID-19 (Beltrán-Corbellini et al., 2020; 
Bénézit et al., 2020; Boscolo-Rizzo et al., 2020; Carignan et al., 2020; 
Giacomelli et al., 2020; Hopkins, Surda, & Kumar, 2020; Hopkins, 
Surda, Whitehead, et al., 2020; Iravani et al., 2020; Kaye et al., 2020; 
Klopfenstein et al., 2020; Kosugi et al., 2020; Lechien, Cabaraux, 
& Chiesa-Estomba et al., 2020a, 2020b; Lechien et al., 2020; 
Lee et al., 2020; Levinson et al., 2020; Mao et al., 2020; Moein 
et al., 2020; Spinato et al., 2020; Vaira et al., 2020, 2020; Wee 
et al., 2020; Yan et al., 2020) High prevalence of these symptoms was 
reported in both studies with an objective assessment of taste and 
smell and self-reported symptom questionnaires (Beltrán-Corbellini 
et al., 2020; Bénézit et al., 2020; Boscolo-Rizzo et al., 2020; Carignan 
et al., 2020; Giacomelli et al., 2020; Hopkins, Surda, & Kumar, 
2020; Hopkins, Surda, Whitehead, et al., 2020; Iravani et al., 2020; 
Kaye et al., 2020; Klopfenstein et al., 2020; Kosugi et al., 2020; 
Lechien, Cabaraux, & Chiesa-Estomba et al., 2020a, 2020b; Lechien 
et al., 2020; Lee et al., 2020; Levinson et al., 2020; Mao et al., 2020; 
Moein et al., 2020; Spinato et al., 2020; Vaira et al., 2020, 2020; 
Wee et al., 2020; Yan et al., 2020) OTD was found to be signifi-
cantly higher in females and in younger patients (Beltrán-Corbellini 
et al., 2020; Bénézit et al., 2020; Boscolo-Rizzo et al., 2020; Carignan 
et al., 2020; Giacomelli et al., 2020; Hopkins, Surda, & Kumar, 
2020; Hopkins, Surda, Whitehead, et al., 2020; Iravani et al., 2020; 
Kaye et al., 2020; Klopfenstein et al., 2020; Kosugi et al., 2020; 
Lechien, Cabaraux, & Chiesa-Estomba et al., 2020a, 2020b; Lechien 
et al., 2020; Lee et al., 2020; Levinson et al., 2020; Mao et al., 2020; 
Moein et al., 2020; Spinato et al., 2020; Vaira et al., 2020, 2020; Wee 
et al., 2020; Yan et al., 2020). Indeed, neurological manifestations of 
COVID-19 such as Guillain–Barré syndrome (GBS) in young people 
are of great concern (Ahmed et al., 2020). However, so far only a few 
cases of COVID-19 associated with GBS have been reported (Webb, 
Wallace, & Martin-Lopez, 2020). GBS can rarely present with taste 
dysfunction (Kogan, Mednick, & Dolgovina, 2011). Although cur-
rently there is no literature on the prevalence of OTD in COVID-19-
positive patients with GBS, we speculate that increased prevalence 
of taste dysfunction in GBS patients may raise the suspicion of the 
infection.
Postviral anosmia has been reported to account for 40% of the 
anosmia cases and one of the leading causes of anosmia in adults 
(Hummel et al., 2017). There is variability in OTD dysfunction among 
patients, and its association with the severity of COVID-19 infection 
is currently uncertain. However, a significant correlation between the 
duration of olfactory and gustatory symptoms and severe COVID-
19 infection has been reported (Vaira et al., 2020). Therefore, hos-
pitalized patients especially younger patients with OTD should be 
monitored carefully. In terms of other COVID-19 symptoms, fever 
and cough were the most common, which is consistent with already 
published medical literature (Boscolo-Rizzo et al., 2020; Carignan 
et al., 2020; Giacomelli et al., 2020; Iravani et al., 2020; Klopfenstein 
et al., 2020; Kosugi et al., 2020; Lechien, Cabaraux, & Chiesa-
Estomba et al., 2020a, 2020b; Lechien et al., 2020; Lee et al., 2020; 
Lovato & Filippis, 2020; Mao et al., 2020; Moein et al., 2020; Spinato 
et al., 2020; Vaira et al., 2020; Wee et al., 2020; Yan et al., 2020).
The presence of anosmia and dysgeusia could help neurolo-
gists and otolaryngologists identify COVID-19 cases early, allowing 
prompt treatment and reduction in infection transmission. It is pos-
sible that symptoms of anosmia and dysgeusia can be used as an 
effective screening tool and aid diagnosis of COVID-19. Zayet et al. 
suggest that the positive predictive value (PPV) for anosmia is 77%, 
dysgeusia 77% and a combination of anosmia plus dysgeusia 83% 
for a positive SARS-CoV-2 real time-polymerase chain reaction (RT-
PCR) test on a nasopharyngeal sample (Zayet et al., 2020). However, 
a key limitation of Zayet et al.'s study is that although RT-PCR on a 
nasopharyngeal sample is specific for COVID-19, it has a sensitivity 
of 56%-83% and may be an inaccurate test to diagnose COVID-19 
(AAO-HNS: Anosmia, Hyposmia; Kokkinakis, Selby, Favrat, Genton, 
& Cornuz, 2020). Therefore, some patients with anosmia and dys-
geusia that tested negative for COVID-19 may be infected with the 
disease. Further research is required to confidently determine the 
utility of OTD dysfunction as an effective screening tool for COVID-
19 infection.
3.9 | Mechanisms underlying olfactory and 
gustatory function in COVID-19 patients
Anosmia associated with COVID-19 has been well documented by 
the literature (Beltrán-Corbellini et al., 2020; Bénézit et al., 2020; 
Boscolo-Rizzo et al., 2020; Carignan et al., 2020; Giacomelli 
et al., 2020; Hopkins, Surda, & Kumar, 2020; Hopkins, Surda, 
Whitehead, et al., 2020; Iravani et al., 2020; Kaye et al., 2020; 
Klopfenstein et al., 2020; Kosugi et al., 2020; Lechien, Cabaraux, & 
Chiesa-Estomba et al., 2020a, 2020b; Lechien et al., 2020; Levinson 
et al., 2020; Lovato & Filippis, 2020; Mao et al., 2020; Moein 
et al., 2020; Spinato et al., 2020; Vaira et al., 2020, 2020; Wee 
et al., 2020; Whitcroft & Hummel, 2020; Yan et al., 2020) Netland 
et al. reported that SARS-CoV can cause neuronal death in mice 
by invading the brain via the nose, which is close to the olfactory 
epithelium (Netland, Meyerholz, Moore, Cassell, & Perlman, 2008). 
Furthermore, the human coronavirus 229E has been isolated in nasal 
discharge from a patient with postviral olfactory dysfunction (Suzuki 
et al., 2007). It has been proposed that SARS-CoV-2 gains entry into 
the central nervous systems via several different ways (Ahmed 
et al., 2020). One of the proposed mechanisms is dissemination and 
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spread from the cribriform plate which is in close contact to the olfac-
tory bulb; this mechanism is postulated to be the underlying cause of 
olfactory dysfunction in patients (Baig, Khaleeq, Ali, & Syeda, 2020). 
Furthermore, the general presence of the virus in the circulation 
can lead to systematic dissemination, allowing the virus to enter 
the cerebral circulation (Ahmed et al., 2020). The brain has been re-
ported to express ACE2 receptors mainly on glial cells, neurons, and 
brain vasculature, making these cells susceptible to attacks by the 
SAR-CoV-2 (Ahmed et al., 2020; Turner, Hiscox, & Hooper, 2004). 
It is well-established that SARS-CoV-2 can exploit the angiotensin-
converting enzyme 2 (ACE2) receptor to gain entry into the cells 
(Ahmed et al., 2020). Viral interaction with the expression of the 
ACE2 receptor in neurones can result in significant damage to the 
neurones without substantial association inflammation previously 
observed with SARS-CoV infection (Ahmed et al., 2020; Netland 
et al., 2008; Wrapp et al., 2020). Therefore, it can be postulated 
that SARS-CoV-2 can cause neuronal damage via the ACE2 receptor 
leading to OTD (Figure 2) (Ahmed et al., 2020). Binding of the virus to 
the ACE2 receptors may cause endothelial dysfunction and also lead 
to serious consequences such as cerebral hemorrhage via unknown 
mechanisms (Ahmed et al., 2020). Another mechanism by which the 
neurotropic SARs-CoV-2 can disseminate through the central nerv-
ous system is by anterograde and retrograde transport with the 
aid of motor proteins such as kinesins and dynein via sensory and 
motor nerve endings, the afferent nerve endings from the vagus 
nerve from the lungs are especially implicated (Ahmed et al., 2020; 
Li, Bai, & Hashikawa, 2020; Swanson & McGavern, 2015). Through 
this mechanism, SARS-CoV-2 could potentially cause gustatory dys-
function. Besides, other ways in which SARS-CoV-2 can cause neu-
rological damage leading to OTD is through a surge of inflammatory 
cytokines leading to cytokine storm syndrome (Ahmed et al., 2020; 
Wan, Yi et al., 2020).
F I G U R E  2   Possible mechanism of interaction between SARs-CoV-2 and the cranial nerves. SARS-CoV-2 can potentially interact with the 
cranial nerves (olfactory, vagus, facial, and glossopharyngeal) via the angiotensin-converting enzyme receptor-2 (ACE2) leading to olfactory 
taste dysfunction. SARS-CoV-2 can also cause damage to the peripheral nerves leading to several other neurological manifestations. 
Angiotensin-converting enzyme 2; ACE2, Original Illustration created using BioRender
F I G U R E  3   Neurological manifestations 
of COVID-19. Guillain–Barré syndrome; 
GBS, Cerebrovascular Accidents; CVA, 
Olfactory and taste dysfunction; OTD 
Original Illustration created using 
BioRender
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TA B L E  4   Neurological manifestations of COVID-19
Author Type of publication
Number of 
COVID−19-Positive 
Patients Results
Neuropathy
Abdelnour et al. (2020) Case Report 1 Bilateral lower limb weakness in 69-year-old male
Wan et al., 2020 Case Report 1 Bell's palsy in a 65-year-old female.
Stroke
Klok et al. (2020) Retrospective 
observational study
184 1.6% develop an ischemic or hemorrhagic stroke
Lodigiani et al. (2020) Retrospective 
observational study
338 2.5% developed an ischemic or hemorrhagic stroke
Mao et al. (2020) Retrospective 
observational study
214 2.8% developed an ischemic or hemorrhagic stroke
Li et al. (2020a) Retrospective 
observational study
219 6.0% developed an ischemic or hemorrhagic stroke
Sharifi-Razavi et al. (2020) Case Report 1 Intracerebral hemorrhage in 79-year-old male with
Haddadi et al. (2020) Case Report 1 Intracerebral hemorrhage in 54-year-old female
Oxley et al. (2020) Case Report 5 Ischemic stroke in patients younger than 50 years of age
Guillain–Barré Syndrome (GBS)
Alberti et al. (2020) Case report 1 71-year-old male patient presented with symptoms 
of subacute onset of paresthesia at limb extremities, 
distal weakness rapidly evolving to severe, flaccid tetra 
paresis over 3 days consistent with the diagnosis of 
GBS
Toscano et al. (2020) Case report 5 Symptoms of GBS including lower limb weakness and 
paresthesia in 4 patients and facial diplegia followed 
by ataxia and paresthesia in 1 patient. Generalized, 
flaccid tetra paresis/tetraplegia over a period of 36 hr 
to 4 days in 4 patients.
Coen et al. (2020) Case report 1 Male patient in his 70’s presented with paraparesis, 
distal allodynia, difficulties in voiding and constipation 
preceding symptoms of myalgia, fatigue, and a dry 
cough.
Camdessanche et al. (2020) Case report 1 Hospitalized	64-year-old	man	COVID−19-positive	
patients developed paresthesia in feet and hands and 
later flaccid severe tetra paresis. Patient was diagnosed 
with GBS on the basis of neurological examination and 
investigations.
Virani et al. (2020) Case report 1 54-year-old male presented with numbness and 
weakness	and	was	diagnosed	with	GBS	and	COVID−19	
positive.
Zhao et al. (2020) Case Report 1 61-year-old female presented with weakness in both 
legs and severe fatigue, progressing over a day, was 
diagnosed with GBS. Later, she developed respiratory 
symptoms	of	COVID−19
Padroni et al. (2020) Case Report 1 70-year-old female was presented to the emergency 
department complaining of asthenia, hands and feet 
paresthesia and gait difficulties progressing within 
1 day. Diagnosed with GBS, later developed respiratory 
symptoms	of	COVID−19
Sedaghat et al. (2020) Case Report 1 65-years- old male patient presented to emergency 
department, with symptoms of acute progressive 
symmetric ascending quadriparesis. 2 weeks prior to 
onset of neurological symptoms, he was diagnosed with 
COVID−19.
(Continues)
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COVID-19 has also been reported to cause other neurological 
manifestations such as seizures, headache, and dizziness (Figure 3) 
(Ahmed et al., 2020; Whittaker, Anson, & Harky, 2020). Table 4 shows 
a summary of neurological manifestations of COVID-19 reported by 
literature (Abdelnour, Abdalla, & Babiker, 2020; Alberti et al., 2020; 
Bernard-Valnet et al., 2020; Camdessanche et al., 2020; Chen, Zhou, 
et al., 2020; Chen, Wu, et al., 2020; Coen et al., 2020; Duong, Xu, & 
Liu, 2020; Guan et al., 2020; Haddadi, Ghasemian, & Shafizad, 2020; 
Huang et al., 2020; Kaya, Kara, Akinci, & Kocaman, 2020; Klok 
et al., 2020; Li et al., 2020; Lodigiani et al., 2020; Mao et al., 2020; 
Moriguchi et al., 2020; Oxley et al., 2020; Padroni et al., 2020; 
Poyiadji et al., 2020; Sedaghat & Karimi, 2020; Sharifi-Razavi, Karimi, 
Author Type of publication
Number of 
COVID−19-Positive 
Patients Results
Headache
Wan et al., 2020 Case series 135 33% of patients reported a headache
Wang et al. (2020) Case series 138 7% of patients reported a headache
Wang et al. (2020) Retrospective review 69 14% of patients reported a headache
Yang et al. (2020) Retrospective review 52 6% of patients reported a headache
Mao et al. (2020) Retrospective study 214 13% patients reported headache
Chen, Wu, et al. (2020) Retrospective study 99 8% patients reported headache
Dizziness
Mao et al. (2020) Retrospective review 214 17% of patients reported dizziness
Chen, Wu, et al. (2020) Retrospective review 113 8% of patients reported dizziness
Wang et al. (2020) Retrospective review 138 6.5% of patients reported dizziness
Myalgia
Wang et al. (2020) Retrospective review 138 34.8% of patients reported myalgia
Zhou et al. (2020) Retrospective review 191 15.2% of patients reported myalgia
Chen, Wu, et al. (2020) Retrospective review 99 11% of patients reported myalgia
Huang et al. (2020) Retrospective review 41 44% of patients reported myalgia or arthralgia
Guan et al. (2020) Retrospective review 1,099 15% of patients reported myalgia or arthralgia
Encephalitis
Ye et al. (2020) Case report 1 Fever, shortness of breath and myalgia with diminished 
consciousness
Bernard-Valnet et al. (2020) Case report 2 1 patient developed tonic-clonic seizures and lumbar 
puncture consistent with viral encephalitis 1 other 
patient developed intense headache with confirmed 
SARS-CoV−2	swab
Poyiadji et al. (2020) Case report 1 58-year-old female presented with symptoms of 
COVID−19	and	altered	mental	state.
Confusion
Chen, Wu, et al. (2020) Retrospective review 99 9.10% of patients reported confusions
Kaya et al. (2020) Case report 1 Patient reported confusion and visual agnosia
Meningitis
Moriguchi et al. (2020) Case report 1 24-year-old male developed symptoms of meningitis/
encephalitis
Status epilepticus/Seizures
Mao et al. (2020) Retrospective review 214 0.5% of patients presented with seizures
Doug et al. (2020) Case Report 1 41-year-old female presented with headache, confusion 
fever, and new-onset seizure
Moriguchi et al. (2020) Case Report 1 24-year-old male bought to the emergency department 
due to convulsions with impaired consciousness. The 
patient had symptoms and imaging was consistent with 
a	diagnosis	of	meningitis	and	patient	was	COVID−19	
positive.
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& Rouhani, 2020; Toscano et al., 2020; Virani et al., 2020; Wan, 
Xiang et al., 2020; Wan, Cao, Fang, Wang, & Huang, 2020; Wang, Hu 
et al., 2020; Wang, Yang, Li, Wen, & Zhang, 2020; Yang et al., 2020; 
Ye, Ren, & Lv, 2020; Zhao, Shen, Zhou, Liu, & Chen, 2020; Zhou 
et al., 2020). It is unclear whether symptoms of OTD alone can be 
used to diagnose COVID-19. However, during this pandemic, COVID-
19 should be considered an important differential diagnosis for pa-
tients presenting with OTD dysfunction. Nevertheless, the presence 
of these symptoms alongside thorough clinical examination, mi-
crobiology tests, and the use of diagnostic imaging techniques can 
help to eliminate differentials and aid the diagnosis of COVID-19. 
Chemosensory assessment and treatments used for postviral OTD 
may also be potentially beneficial in COVID-19 patients (Whitcroft 
& Hummel, 2020).
3.10 | Limitations
Our review, only focussed on COVID-19-positive patients, however, 
these symptoms may also be present in patients that were COVID-
19-negative. Therefore, to fully establish the diagnostic value of 
OTD comparison of symptoms between both COVID-19-positive 
and COVID-19-negative patients should be investigated. The risk 
versus benefit of researching COVID-19 and OTD also needs to be 
highlighted. In studies with an objective assessment of OTD, there 
is possible risk of infection transmission due to physician–patient 
contact. Although telephone interviews and online surveys can help 
to minimize this risk, there is a potential bias associated with subjec-
tive assessment of symptoms. Another key limitation of our review 
is that we did not consider the limitations of the method of assess-
ment of OTD in the studies. Studies used either individualized online 
surveys or specific tests such as CCCRC and SNOT-22. The differ-
ences between the questionnaires and reliability of the objective 
tests in reporting OTD were not taken into consideration. Currently, 
in clinical practice, subjective assessment of chemosensory func-
tion is relied upon as there is a limited correlation with objective 
measures. Furthermore, key confounding factors such as underly-
ing respiratory disease or hay fever were not discussed. Moreover, 
the follow-up duration of the recovery of patients with OTD is not 
well documented. Finally, it is possible that some studies would have 
rushed to publish presenting incomplete data.
4  | IMPLIC ATIONS FOR FURTHER 
RESE ARCH
Currently, the literature on COVID-19 and OTD is limited and is 
mainly confined to reports of self-reported symptoms. Further stud-
ies with large cohort sizes and global collaborations with an objec-
tive assessment of OTD are required to fully establish the merit of 
these symptoms in the diagnosis of COVID-19. OTD can also be pre-
sent in non-COVID-19 patients (Kosugi et al., 2020). Kosugi et al. 
reported OTD in patients which subsequently tested negative for 
COVID-19 (Kosugi et al., 2020). Future studies with larger cohort 
sizes comparing the difference in duration and prevalence of OTD 
in COVID-19-positive patients compared to non-COVID-19 patients 
would help elucidate the true diagnostic value of these symptoms in 
COVID-19. OTD tends to significantly affect patients who are female 
and from younger age groups; however, the reasons are unknown. 
Furthermore, there is uncertainty regarding the utility of these 
symptoms as a predictor of severe COVID-19 infection. Therefore, 
further research is required to clarify the association between OTD 
and the severity of COVID-19 infection. The pathophysiology of 
OTD in COVID-19 remains to be determined.
5  | CONCLUSION
Clinical examination of the olfactory nerve is often neglected in 
routine clinical practice. The COVID-19 pandemic has highlighted 
the importance of this much forgotten cranial nerve. COVID-19 
patients frequently report symptoms of anosmia and dysgeusia, 
and therefore, these symptoms should raise a high index of sus-
picion for COVID-19 infection especially in young and female 
patients. The presence of these symptoms alongside objective 
clinical assessment would help to make a diagnosis. Further re-
search is warranted as currently both the performance of these 
symptoms as predictors of COVID-19 infection and their diagnos-
tic value is uncertain.
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